Reading ASTH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.

QuarterlyIQ Insights · ASTH

Price

Price, valuation, and the composite score on the same time axis. Scroll over the price chart to zoom.

Price

Daily closes. Earnings/event dots inline.

Close 2026-06-12

Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.

EarningsMaterial event

What it's worth (estimated)

A consensus fair price across 6 valuation methods, at three horizons. Current price $38.62. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.

12-month· primaryfair

$40.74consensus

Range $35.63 – $48.16

vs price: -5% below

Method agreement — · 6 methods

No-growth: today's peer multiple on trailing earnings. The headline read.

3-yearinexpensive

$135.12consensus

Range $118.15 – $152.08

vs price: -71% below

Method agreement — · 2 methods

Embeds projected growth. Leans optimistic by design. Upside context.

5-yearinexpensive

By method

Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.

Method	Horizon	Est. price	Multiple	Per-share input	EPS source	Confidence
Peer EV/EBITDA	12M	$6.98	5.9	3.10	TTM	high
Peer P/FCF	12M	$51.05	16.2	3.16	TTM	high
Peer P/E	12M	$34.93	14.5	2.41	TTM	high
Peer P/S	12M	$48.03	0.9	52.78	TTM	high
Own P/E history	12M

P/E history

Monthly trailing P/E with quartile reference lines.

75 monthly points available

Coming next

A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.